Heather A. Wakelee, MD, Stanford University Medical Center

Articles by Heather A. Wakelee, MD, Stanford University Medical Center

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO.

Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

ByHeather A. Wakelee, MD, Stanford University Medical Center

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

WCLC Updates in Small Cell Lung Cancer

ByStephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Heather A. Wakelee, MD, Stanford University Medical Center

March 5th 2021

Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.

WCLC Updates in Locally Advanced NSCLC

ByStephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Heather A. Wakelee, MD, Stanford University Medical Center

March 5th 2021

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).

WCLC Updates in Neoadjuvant Therapy for NSCLC

ByStephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Heather A. Wakelee, MD, Stanford University Medical Center

March 5th 2021

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

WCLC Updates in Immunotherapy for NSCLC

ByStephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Heather A. Wakelee, MD, Stanford University Medical Center

February 26th 2021

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

WCLC Updates on the Emergence of ADCs in NSCLC

ByStephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Heather A. Wakelee, MD, Stanford University Medical Center

February 26th 2021

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC

ByStephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Sarah Goldberg, MD, MPH, Yale School of Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Heather A. Wakelee, MD, Stanford University Medical Center

February 26th 2021

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).